Hermetica Superfood Encyclopedia
The Short Answer
EPA (eicosapentaenoic acid, 20:5n-3) and DHA (docosahexaenoic acid, 22:6n-3) are long-chain n-3 polyunsaturated fatty acids biosynthesized in marine microalgae via sequential desaturation and elongation of α-linolenic acid, and they exert anti-inflammatory and neuroprotective effects by integrating into cell membranes, acting as ligands for PPARα/γ receptors, inhibiting NF-κB signaling, and serving as biosynthetic precursors to specialized pro-resolving mediators including resolvins and protectins. Meta-analyses of fish-oil EPA/DHA trials — to which algal-derived EPA/DHA is considered biochemically equivalent — demonstrate approximately 15–20% reductions in serum triglycerides at doses of 2–4 g/day and statistically significant reductions in major adverse cardiovascular events in high-risk populations, as documented in the REDUCE-IT trial (icosapentaenoic acid, 4 g/day, HR 0.75, 95% CI 0.68–0.83).
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordalgal EPA DHA benefits
Algal EPA/DHA — botanical close-up
Health Benefits
**Triglyceride Reduction**
EPA and DHA downregulate hepatic SREBP-1c and activate PPARα, suppressing de novo lipogenesis and increasing fatty acid β-oxidation, producing clinically meaningful reductions in serum triglycerides of 20–50% at doses of 2–4 g/day in hypertriglyceridemic individuals.
**Cardiovascular Risk Reduction**
By reducing pro-inflammatory eicosanoid production (shifting from n-6-derived thromboxane A2 and prostaglandin E2 toward less potent n-3 analogs), EPA and DHA decrease platelet aggregation, endothelial inflammation, and atherosclerotic plaque progression, translating to reduced major cardiovascular event rates in high-risk populations.
**Brain Health and Cognitive Function**
DHA constitutes approximately 30–40% of polyunsaturated fatty acids in neuronal membranes and is essential for synaptic membrane fluidity, neurotransmitter receptor function, and neuroprotectin D1 synthesis, with observational data linking higher DHA status to reduced risk of cognitive decline and dementia.
**Systemic Anti-Inflammatory Action**: EPA and DHA are biosynthetic precursors to E-series and D-series resolvins, protectins, and maresins
specialized pro-resolving mediators (SPMs) that actively terminate acute inflammation, reduce neutrophil infiltration, and promote macrophage efferocytosis without immunosuppression.
**Perinatal Neurodevelopment**
Maternal DHA supplementation (200–600 mg/day) supports fetal brain and retinal development, as DHA accumulates rapidly in the fetal brain during the third trimester; algal DHA provides a mercury-free, vegan-compatible source appropriate for pregnant and lactating individuals.
**Mood and Mental Health Support**
Epidemiological data and several randomized trials associate low EPA and DHA status with elevated risk of depression; EPA in particular appears to modulate serotonergic and dopaminergic signaling and reduce neuroinflammatory cytokine levels (IL-6, TNF-α) implicated in depressive pathophysiology.
**Joint and Inflammatory Condition Management**
Incorporation of EPA and DHA into immune cell phospholipids reduces leukotriene B4 production and prostaglandin E2 synthesis, with multiple RCTs in rheumatoid arthritis populations showing reduced morning stiffness, tender joint counts, and NSAID use at combined EPA+DHA doses of 3–6 g/day.
Origin & History
Natural habitat
Marine microalgae are single-celled photosynthetic organisms distributed across global ocean ecosystems, from coastal temperate waters to open-ocean environments, and represent the evolutionary origin of EPA and DHA in the marine food chain. Commercially cultivated species such as Nannochloropsis sp., Schizochytrium sp., Crypthecodinium cohnii, and Phaeodactylum tricornutum are grown in controlled photobioreactors or fermentation tanks under optimized conditions of temperature, light intensity, and nitrogen availability to maximize lipid yield. Unlike fish oil, algal PUFA production does not depend on wild fisheries, arable land, or seasonal harvests, making it one of the most scalable and sustainable long-chain omega-3 sources available for human supplementation.
“Marine microalgae have no documented history of intentional human therapeutic use in any traditional medicine system; unlike fish liver oils, which were used empirically in Northern European and Japanese coastal cultures for centuries (cod liver oil documented in British medical literature from the 18th century), microalgae-derived PUFA concentrates are an entirely modern innovation emerging from marine biotechnology research in the late 20th century. The commercial development of algal DHA was pioneered in the 1980s–1990s by Martek Biosciences Corporation (now DSM), which identified Crypthecodinium cohnii and later Schizochytrium sp. as viable fermentation organisms for producing DHA at industrial scale, originally targeting infant formula fortification as a response to epidemiological evidence linking DHA to neurological development outcomes. The recognition that microalgae are the true trophic origin of marine EPA and DHA — with fish accumulating these fatty acids only by consuming algae or algae-eating organisms — reframed the scientific narrative around omega-3 sourcing and catalyzed ongoing research into algal biotechnology as a sustainable solution to collapsing global fish stocks. Today, algal EPA/DHA represents the primary clinically validated vegan omega-3 source and has been incorporated into infant formulas, functional foods, dietary supplements, and aquaculture feeds globally, representing a rare example of a nutritional ingredient that transitioned from basic marine biology research to widespread consumer use within a single generation.”Traditional Medicine
Scientific Research
The broader evidence base for EPA and DHA is among the most extensively studied in nutritional science, encompassing hundreds of randomized controlled trials, systematic reviews, and Cochrane meta-analyses; however, clinical trials specifically isolating marine microalgae-derived EPA/DHA (as distinct from fish oil) in human subjects are limited, with most evidence extrapolated from fish oil RCTs given assumed biochemical equivalence. Bioavailability comparison studies — including a crossover RCT by Arterburn et al. (2008, n=32) — demonstrated that DHA from algal oil (Schizochytrium-derived) produced equivalent increases in plasma DHA and EPA status compared to cooked salmon, supporting functional equivalence for regulatory and clinical purposes. Landmark cardiovascular trials such as REDUCE-IT (Bhatt et al., NEJM 2019, n=8,179) using high-dose icosapentaenoic acid (4 g/day) demonstrated a 25% relative risk reduction in major adverse cardiovascular events (HR 0.75, 95% CI 0.68–0.83), while ASCEND (n=15,480) and ORIGIN (n=12,536) trials using combined EPA+DHA at 1 g/day showed neutral or modest cardiovascular effects, suggesting dose- and formulation-dependency. Meta-analyses of omega-3 supplementation in depression (e.g., Sublette et al., 2011; Mocking et al., 2016) support EPA-predominant formulations (>60% EPA) as adjunctive treatments for major depressive disorder, and Cochrane reviews on rheumatoid arthritis consistently report significant reductions in joint pain and NSAID requirements, though effect sizes are moderate and heterogeneity across trials is substantial.
Preparation & Dosage
Traditional preparation
**Algal Oil Softgels (DHA-predominant, e.g., Schizochytrium-derived)**
200–500 mg DHA per capsule; typical supplemental doses for general health are 200–300 mg DHA/day for adults; 200–600 mg/day for pregnant and lactating individuals per EFSA and WHO guidance
**Algal Oil Softgels (EPA+DHA combined, e.g., Nannochloropsis-derived)**
1–2 g combined EPA+DHA/day are used for anti-inflammatory and general cardiovascular support
Emerging products provide balanced EPA:DHA ratios; doses of .
**High-Dose Prescription-Equivalent Use**
3–4 g/day of combined EPA+DHA or EPA alone; achieving this with algal oil requires multiple capsules and should be medically supervised
For triglyceride reduction, clinical trials support .
**Liquid Algal Oil**
Available in bulk or retail form for incorporation into foods or beverages; oxidative stability requires refrigeration and nitrogen-flushed packaging due to high PUFA content and susceptibility to lipid peroxidation.
**Microalgae Biomass Powder**
Whole dried microalgae (e.g., Nannochloropsis) incorporated into functional foods or feed; PUFA bioavailability may differ from extracted oil forms and depends on cell wall disruption during processing.
**Standardization**
Commercial algal DHA products are typically standardized to ≥40% DHA by weight of total oil; EPA-containing algal oils vary more widely and should specify EPA and DHA content in mg per serving.
**Timing**
Taking algal oil with a fat-containing meal significantly improves EPA and DHA absorption (estimated 50–60% increase) by stimulating bile secretion and chylomicron assembly; evening administration with dinner is a practical recommendation.
Nutritional Profile
Extracted algal oils are nearly pure lipid concentrates (>90% total lipids by weight) with negligible protein or carbohydrate content; DHA typically comprises 35–50% of total fatty acids in Schizochytrium-derived oils, while Nannochloropsis-derived EPA oils may contain 15–30% EPA with lower DHA fractions. Minor lipid components include phosphatidylcholine (a preferred carrier form that may enhance neural DHA uptake compared to triglyceride forms), sterols (including fucosterol and brassicasterol in diatoms), carotenoids (particularly fucoxanthin in diatoms and astaxanthin in some species), and tocopherols (vitamin E isomers added as antioxidant stabilizers in commercial preparations). Bioavailability of EPA and DHA from algal triglyceride oil is comparable to fish oil triglycerides (estimated 95% absorption in the presence of dietary fat) and superior to ethyl ester forms, which require pancreatic lipase-mediated re-esterification for lymphatic absorption; phospholipid-bound EPA/DHA (as found in krill oil and some algal preparations) may offer enhanced brain uptake via the Mfsd2a transporter pathway. Whole microalgae biomass additionally provides β-glucans, chlorophylls, and species-specific pigments, but lipid extraction for supplement production removes most non-lipid phytochemicals.
How It Works
Mechanism of Action
EPA and DHA exert their primary molecular effects by physically incorporating into phospholipid bilayers of cell membranes — particularly at the sn-2 position of phosphatidylcholine and phosphatidylethanolamine — where they alter membrane microdomain organization (lipid rafts), reduce bilayer rigidity, and modulate the conformation and signaling efficiency of embedded receptors including toll-like receptor 4 (TLR4) and GPR120, the latter of which transduces anti-inflammatory signals through β-arrestin-2 and TAB1 sequestration, suppressing TAK1-mediated activation of NF-κB and subsequent transcription of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. As substrates for 5-lipoxygenase and cyclooxygenase-2, EPA and DHA competitively displace arachidonic acid, producing 3-series prostaglandins and 5-series leukotrienes that are significantly less potent agonists at eicosanoid receptors compared to their n-6-derived counterparts, while also serving as precursors for enzymatically generated specialized pro-resolving mediators (resolvins E1/E2 from EPA and resolvins D1-D6, protectin D1, and maresins from DHA) that actively resolve inflammation via FPR2/ALX and ChemR23 receptors. At the transcriptional level, both EPA and DHA are endogenous ligands for peroxisome proliferator-activated receptors (PPARα and PPARγ), activating gene networks that promote fatty acid oxidation, suppress SREBP-1c-driven lipogenesis, and reduce hepatic triglyceride export, while DHA-derived neuroprotectin D1 upregulates anti-apoptotic BCL-2 family proteins and reduces amyloid precursor protein processing in neuronal cells. In microalgae, biosynthesis proceeds via front-end desaturase enzymes (Δ5- and Δ6-desaturases) and elongases acting on ALA through the n-3 pathway, with species-specific differences — for example, diatoms such as Phaeodactylum tricornutum accumulate EPA preferentially via Δ5-desaturase activity, while thraustochytrids including Schizochytrium sp. utilize a polyketide synthase-like PKS pathway for DHA synthesis that bypasses conventional aerobic desaturation.
Clinical Evidence
The most definitive cardiovascular evidence comes from REDUCE-IT (2019), which enrolled 8,179 statin-treated patients with elevated triglycerides and found that high-dose EPA alone (4 g/day as icosapentaenoic acid ethyl ester) reduced the composite primary cardiovascular endpoint by 25% versus mineral oil placebo — though debate persists regarding whether mineral oil inflated the placebo arm's risk. At lower doses (1 g/day combined EPA+DHA), ASCEND and ORIGIN trials found no significant reduction in cardiovascular events in diabetic and dysglycemic populations respectively, reinforcing the dose-dependency of cardiovascular benefit and suggesting that standard supplemental doses may be insufficient for cardiovascular event reduction in lower-risk individuals. For triglyceride lowering, multiple RCTs and a Cochrane review confirm that 3–4 g/day EPA+DHA reduces fasting triglycerides by 20–50% in hypertriglyceridemic subjects, with this effect sufficiently established that prescription omega-3 formulations (Lovaza, Vascepa) hold regulatory approval for this indication. Microalgae-specific clinical trial data remain sparse and underpowered, but bioequivalence to fish-derived omega-3 is well supported at the pharmacokinetic level, and the absence of marine contaminants (methylmercury, PCBs, dioxins) in controlled algal cultivation is a clinically meaningful safety advantage.
Safety & Interactions
Algal EPA and DHA are generally recognized as safe (GRAS) for the amounts used in foods and supplements; at typical supplemental doses (200–2000 mg/day), adverse effects are minimal and primarily gastrointestinal — including fishy aftertaste (less pronounced with algal vs. fish sources), burping, and loose stools — particularly when taken on an empty stomach. At pharmacological doses above 3 g/day EPA+DHA, clinically relevant antiplatelet and mild anticoagulant effects may potentiate the action of anticoagulant medications (warfarin, direct oral anticoagulants, heparin) and antiplatelet agents (aspirin, clopidogrel), warranting monitoring of bleeding time and INR in susceptible individuals; however, the clinical significance of this interaction at doses below 3 g/day appears low in current evidence. LDL cholesterol may increase modestly (5–10%) in some individuals taking high-dose EPA+DHA, particularly in hypertriglyceridemic subjects, though this effect is typically not observed with EPA-only formulations; algal oils are free from methylmercury, PCBs, dioxins, and other persistent organic pollutants that pose contamination risks with fish-derived oils. Algal EPA/DHA is considered safe during pregnancy and lactation at recommended doses (200–600 mg DHA/day) and is actively recommended by multiple obstetric and nutritional bodies (WHO, EFSA, American Academy of Pediatrics); no established tolerable upper intake level has been set by most regulatory agencies, though the FDA has acknowledged safety of up to 3 g/day from dietary supplements without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Eicosapentaenoic acid (EPA, 20:5n-3)Docosahexaenoic acid (DHA, 22:6n-3)Algal oil omega-3Marine microalgae PUFAn-3 long-chain polyunsaturated fatty acidsSchizochytrium DHA oilNannochloropsis EPA oil
Frequently Asked Questions
Is algal DHA as effective as fish oil for raising omega-3 levels?
Yes — a crossover pharmacokinetic study by Arterburn et al. (2008, n=32) demonstrated that DHA from Schizochytrium algal oil raised plasma DHA concentrations equivalently to cooked salmon, confirming bioequivalence at the absorption and tissue-incorporation level. EPA levels also rose in that study due to retroconversion of DHA to EPA, and omega-3 index improvements were statistically indistinguishable between the two sources, supporting algal oil as a fully viable fish-oil alternative.
How much algal DHA should I take during pregnancy?
WHO, EFSA, and the American Academy of Pediatrics recommend a minimum of 200 mg DHA per day during pregnancy and lactation to support fetal brain and retinal development, with some guidelines suggesting up to 600 mg/day for individuals with low baseline dietary omega-3 intake. Algal DHA is the preferred source for pregnant individuals seeking to avoid methylmercury and other marine pollutants found in some fish species, and it is used in commercial infant formulas globally for this reason.
Can algal EPA and DHA lower triglycerides?
Yes — combined EPA+DHA at doses of 2–4 g/day consistently reduces fasting serum triglycerides by 20–50% in hypertriglyceridemic individuals across multiple RCTs, a finding sufficiently robust that prescription omega-3 formulations (Lovaza, Vascepa) are FDA-approved for this indication. The mechanism involves PPARα activation reducing hepatic VLDL triglyceride synthesis and secretion, along with increased lipoprotein lipase-mediated plasma triglyceride clearance; typical supplemental doses of 200–500 mg/day produce more modest effects and are not adequate for therapeutic triglyceride lowering.
What is the difference between EPA and DHA, and which microalgae produce each?
EPA (eicosapentaenoic acid, 20:5n-3) is a 20-carbon omega-3 primarily associated with anti-inflammatory eicosanoid and resolvin synthesis, while DHA (docosahexaenoic acid, 22:6n-3) is a 22-carbon omega-3 critical for neuronal membrane structure and neuroprotectin synthesis. Nannochloropsis sp. and Phaeodactylum tricornutum (diatoms) produce predominantly EPA (15–30% of total lipids), whereas Schizochytrium sp. and Crypthecodinium cohnii accumulate high proportions of DHA and are the primary commercial sources for algal DHA supplementation.
Are there any drug interactions with algal omega-3 supplements?
At doses above 3 g/day EPA+DHA, algal omega-3 supplements can potentiate anticoagulant medications (warfarin, apixaban, rivaroxaban) and antiplatelet drugs (aspirin, clopidogrel) by inhibiting platelet aggregation and thromboxane A2 production, potentially increasing bleeding risk; INR monitoring is prudent for warfarin users starting high-dose supplementation. At standard supplemental doses below 2 g/day, clinically significant drug interactions are uncommon, though caution is still appropriate in patients on dual antiplatelet therapy or undergoing surgical procedures.
What dose of marine microalgae EPA/DHA is needed to see meaningful triglyceride reductions?
Clinical studies demonstrate that 2–4 grams daily of combined EPA and DHA from marine microalgae can produce triglyceride reductions of 20–50% in individuals with elevated triglycerides. This effect occurs because EPA and DHA suppress hepatic lipogenesis by downregulating SREBP-1c and activating PPARα, which increases fatty acid oxidation. Doses below 2 grams daily typically show minimal triglyceride-lowering effects, while doses above 4 grams daily provide diminishing returns in most populations.
How do EPA and DHA from marine microalgae reduce cardiovascular inflammation?
EPA and DHA are precursors to specialized pro-resolving mediators and suppress the production of pro-inflammatory eicosanoids (such as arachidonic acid-derived inflammatory compounds), shifting immune signaling toward anti-inflammatory pathways. This reduction in systemic inflammation helps lower cardiovascular risk by decreasing endothelial dysfunction, arterial stiffness, and atherosclerotic progression. The anti-inflammatory effect is most pronounced at doses of 2–3 grams daily sustained over 8–12 weeks.
Who benefits most from marine microalgae EPA/DHA supplementation?
Individuals with hypertriglyceridemia, elevated cardiovascular risk, or low fish consumption benefit most from algal EPA/DHA, as these populations show the greatest magnitude of triglyceride reduction and inflammatory markers improvement. Vegans, vegetarians, and those with fish allergies also represent key beneficiary groups since marine microalgae provide the only reliable plant-derived source of preformed EPA and DHA. Pregnant and lactating women may benefit for fetal neurodevelopment support, though individual dosing should be discussed with a healthcare provider.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w pufas-epadha-marine-microalgae curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
